RAF and MEK inhibitor therapy in adult patients with brain tumors: a case-based overview and practical management of adverse events.

Journal Article (Journal Article;Review)

Targeted therapy has gained mainstream attention with notable successes against specific genetic mutations in many cancers. One particular mutation, the BRAF V600E mutation, is present in a small subset of gliomas in adults. Although clinical experience and trial data of RAF-targeted therapy in adults with glioma are lacking at this time, the poor prognosis of adult high-grade glioma has led neuro-oncology practitioners to consider the use of targeted therapy in these patients. In this manuscript, we describe the use of RAF and MEK inhibitors in adults with recurrent glioma. We discuss the utility of these agents, describe their toxicities, and give examples of management strategies. Given the significant toxicities of RAF and MEK inhibitors, along with the long potential duration of treatment, neuro-oncology providers should counsel patients carefully before initiating therapy and monitor them closely while undergoing treatment with RAF-targeted therapy.

Full Text

Duke Authors

Cited Authors

  • Schreck, KC; Patel, MP; Wemmer, J; Grossman, SA; Peters, KB

Published Date

  • July 2020

Published In

Volume / Issue

  • 7 / 4

Start / End Page

  • 369 - 375

PubMed ID

  • 32765888

Pubmed Central ID

  • PMC7393273

International Standard Serial Number (ISSN)

  • 2054-2577

Digital Object Identifier (DOI)

  • 10.1093/nop/npaa006


  • eng

Conference Location

  • England